Orchid - India Ratings

More documents

Recommendations

Info

For the long term, specific projects for regulatedmarket entry are advancing well• US FDA inspection for Cephalexin (oral) plant at Alathursuccessfully completed in November 2002 ; paves the way for USmarket entry early 2003• Inspection for Cefazolin (sterile) plant at Alathur is due in Q2 of2003; followed by US market entry• New US FDA compliant sterile, non-sterile and intermediate blocksat Alathur will be commissioned by Q3 of 2002-03; will supportentry of all key cephs to US progressively from 2003-04 based onDMFs• Non-infringing processes developed for all cephalosporinproducts and filed for patent protection• More filings have been made for COS with EDQM ; will supportbroader European penetration from 2003-0413
The US Ceph generics business will develop ina significant way from 2005• Broad-based alliance with a leading global genericscompany finalised for the full range of <strong>Orchid</strong>’scephalosporin formulations, to be marketed in US andCanada• New oral and sterile cephalosporin formulations plants atIrungattukottai (near Chennai) to be commissioned in Q4of 2002-03, will help formulations export to US as well asother regulated and non-regulated markets• A discrete organisation and leadership with end-to-endconnectivity has been established to fast-track the USgenerics business14
Page 1 and 2: CONFIDENTIALProfile and StrategyDec
Page 3: Orchid’s web of six core capabili
Page 6 and 7: Orchid’s strategy in 1999 aimed a
Page 8 and 9: Orchid drew up a new business strat
Page 10 and 11: Projects executed / under execution
Page 12 and 13: Performance in 2002-03 will be sign
Page 16 and 17: In research and other knowledge int
Page 18 and 19: The organic strategy is supplemente
Page 20 and 21: The current growth initiatives will
Page 22: 21Thank You

Orchid - India Ratings

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?